Association of miRNA − 320 expression level and its target gene endothelin-1 with the susceptibility and clinical features of polycystic ovary syndrome

Table 1 Clinical, anthropometric and laboratory characteristics of studied groups

	Control group (mean ± SD) (n = 40)	PCO patients (mean ± SD) (n = 60)	P
Systolic blood pressure (mm Hg)	125.4 ± 7.16	130.6 ± 7.3	<0.001*
Diastolic blood pressure (mm Hg)	85.6 ± 3.96	87.5 ± 4.9	<0.001*
Hirsutism score	5.38 ± 0.594	7.41 ± 3.02	<0.001*
Body mass index (kg/m2)	24.9 ± 2.48	33.2 ± 5.731	<0.001*
Waist/hip ratio	0.98 ± 0.191	1.26 ± 0.28	<0.001*
Ovarian volume	3.58 ± 0.612	7.35 ± 2.744	<0.001*
AFC	2.58 ± 0.612	7.35 ± 2.744	<0.001*
Total cholesterol (mg/dL)	167.5 ± 19.26	185.0 ± 124.7	<0.001*
Triglycerides (mg/dL)	144.55 ± 20.4	192.2 ± 42.05	<0.001*
LDL cholesterol (mg/dL)	106.24 ± 4.24	125.8 ± 18.11	<0.001*
HDL cholesterol (mg/dL)	57.5 ± 7.33	40.3 ± 9.42	<0.001*
Fasting plasma glucose (mg/dL)	83.9 ± 8.40	95.3 ± 15.61	<0.001*
HbA1c (%)	5.5 ± 0.596	6.03 ± 0.42	<0.001*
Fasting serum insulin (lU/mL)	6.8 ± 1.44	17.5 ± 10.41	<0.001^*
HOMA-IR	1.42 ± 0.322	3.7 ± 2.32	<0.001*
HOMA-β	166.9 ± 76.9	127.7 ± 81.84	0.016
FSH (mIU/mL)	4.8 ± 0.972	5.5 ± 1.538	<0.001*
LH (mIU/mL)	5.52 ± 1.21	6.97 ± 1.53	<0.001*
LH/FSH	1.2 ± 0.43	13 ± 0.39	0.145
DHEA-S (mg/mL)	0.99 ± 0.31	1.3 ± 0.77	<0.001*
Androstenedione (ng/mL)	1.17 ± 0.34	1.7 ± 0.5	0.015
Total testosterone (ng/mL)	0.50 ± 0.145	0.7 ± 0.32	<0.001*

FSI fasting serum insulin, FPG fasting plasma glucose, AFC antral follicle cells, HOMA-IR homeostasis model assessments of insulin resistance, DHEA dehydroepiandrosterone, *P < 0.05 when compared with control group

ISSN: 1757-2215